18. Use of an intravenous immunoglobulin (IVIG) composition in the manufacture of a medicament for treating Alzheimer's disease in a subject, wherein administration of the IVIG composition in the subject has been deemed effective according to steps (a) to (d) of the method of claim 14, wherein the IVIG composition is to be administered at about 0.2 to 2 grams per kg body weight of the subject per month, preferably at about 0.4 gram per kg body weight of the subject twice a month.

19. The use according to claim 18, wherein the IVIG composition is to be administered once a week, twice a week, once a month, or twice a month.

20. The use according to claim 18, wherein the IVIG composition is to be administered intravenously or subcutaneously.